Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) Byrd, J. C., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J., Grant, B., Jones, J. A., Wierda, W. G., Zhao, W., Heerema, N. A., Johnson, A. J., Anh Tran, A., Clow, F., Kunkel, L., James, D. F., O'Brien, S. AMER SOC HEMATOLOGY. 2012
View details for Web of Science ID 000313838900268